Paclitaxel therapy is promising in secondary progressive multiple sclerosis

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1227, 2000-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management of Secondary-Progressive Multiple Sclerosis

By Gavin Giovannoni

CNS Drugs, Vol. 18, Iss. 10, 2004-01 ,pp. : 653-669

Adis International

Access to resources Recommend Favorite

Rituximab for Secondary Progressive Multiple Sclerosis: A Case Series

By Rommer Paulus S. Patejdl Robert Winkelmann Alexander Benecke Reiner Zettl Uwe K.

CNS Drugs, Vol. 25, Iss. 7, 2011-07 ,pp. : 607-613

Adis International

Access to resources Recommend Favorite

Interferon- -1b: A Review of its Use in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

By McCormack P.L. Scott L.J.

CNS Drugs, Vol. 18, Iss. 8, 2004-01 ,pp. : 521-546

Adis International

Access to resources Recommend Favorite

Patients with secondary progressive multiple sclerosis (MS) may not benefit from treatment with IV immunoglobulin G (IVIG)

Inpharma, Vol. 1, Iss. 1457, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Advances in Antioxidative Therapy of Multiple Sclerosis

Current Medicinal Chemistry, Vol. 20, Iss. 37, 2013-11 ,pp. : 4720-4730

Bentham Science Publishers

Access to resources Recommend Favorite